BioTime, Inc. Share Price NYSE
Stocks
US09066L1052
Biotechnology & Medical Research
| Market Cap | 26Cr 22Cr 21Cr 19Cr 36Cr 2.45TCr 36Cr 251.21Cr 97Cr 1.25TCr 96Cr 94Cr 4.02TCr | P/E 2026 * |
-15x | P/E 2027 * | -9.68x |
|---|---|---|---|---|---|
| Enterprise Value | 26Cr 22Cr 21Cr 19Cr 36Cr 2.45TCr 36Cr 251.21Cr 97Cr 1.25TCr 96Cr 94Cr 4.02TCr | EV / Sales 2026 * |
16.8x | EV / Sales 2027 * | 15.2x |
| Free-Float |
95.14% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: BioTime, Inc.
| 1 day | +7.37% |
| Manager | Title | Age | Since |
|---|---|---|---|
Brian Culley
CEO | Chief Executive Officer | 54 | 17/09/2018 |
Jill Howe
DFI | Director of Finance/CFO | 50 | 14/11/2022 |
Priyantha Herath
CTO | Chief Tech/Sci/R&D Officer | - | 01/04/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Neal Bradsher
BRD | Director/Board Member | 60 | 01/07/2009 |
Deborah Andrews
BRD | Director/Board Member | 68 | 11/04/2014 |
Michael Mulroy
CHM | Chairman | 60 | 27/04/2024 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +7.37% | -11.55% | - | - | 26Cr | |
| +1.29% | +2.94% | +2.26% | +29.72% | 4.67TCr | |
| +1.30% | +1.58% | +44.15% | +35.50% | 4.44TCr | |
| +0.95% | -6.02% | +342.72% | +532.41% | 4.13TCr | |
| +4.23% | +3.35% | +9.35% | +94.73% | 4.16TCr | |
| +1.11% | +1.45% | +11.52% | +45.96% | 3.01TCr | |
| +1.94% | +4.84% | +25.19% | +159.21% | 1.74TCr | |
| +0.37% | -10.32% | - | - | 1.56TCr | |
| -0.13% | +6.12% | +24.41% | +42.14% | 1.55TCr | |
| +0.24% | +25.43% | -11.57% | - | 1.41TCr | |
| Average | +1.86% | +3.55% | +56.00% | +134.24% | 2.96TCr | |
| Weighted average by Cap. | +1.53% | +2.11% | +70.14% | +142.19% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.52Cr 1.32Cr 1.25Cr 1.14Cr 2.13Cr 145.55Cr 2.13Cr 15Cr 5.76Cr 74Cr 5.71Cr 5.58Cr 239.26Cr | 1.68Cr 1.47Cr 1.38Cr 1.26Cr 2.36Cr 161.28Cr 2.36Cr 17Cr 6.38Cr 82Cr 6.32Cr 6.18Cr 265.11Cr |
| Net income | -2.26Cr -1.97Cr -1.86Cr -1.69Cr -3.17Cr -216.9Cr -3.18Cr -22Cr -8.58Cr -110.49Cr -8.5Cr -8.32Cr -356.54Cr | -3.44Cr -3Cr -2.83Cr -2.58Cr -4.83Cr -329.94Cr -4.84Cr -34Cr -13Cr -168.07Cr -13Cr -13Cr -542.36Cr |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
